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Natural Killer Cells in Placentation and Cancer: Implications for Hypertension 16 
during Pregnancy 17 
Abstract 18 
Hypertension during pregnancy is the most common medical condition encountered 19 
during gestation. Despite this, knowledge of the mechanisms that underlie the 20 
disease and the development of new therapies are limited. Hypertension during 21 
pregnancy and some forms of cancer confer an increased risk to the development of 22 
cardiovascular disease later in life; one mechanism which may link these conditions 23 
is the involvement of natural killer (NK) cells. Whilst immunology and immunotherapy 24 
are well-developed areas in oncology; the complex mechanisms of the immune 25 
system in health and disease at the maternal-fetal interface are less well-defined. 26 
Natural killer (NK) cells have emerged as key immune cells involved in physiology 27 
and pathology of pregnancy. These small lymphocytes are present in the decidua 28 
(the uterine-specific uNK cells) and are distinct from peripheral NK cells. The uNK 29 
cell population plays a vital role in mediating trophoblast invasion and affecting 30 
decidual vascular remodelling whereas the role of the peripheral NK cell population 31 
during pregnancy is less well-defined. This review will give an overview of NK cell 32 
biology followed by a discussion of the current evidence for the role of uterine and 33 
peripheral NK cells at the maternal-fetal interface in health and disease. 34 
Furthermore, examples of NK cell research from cancer biology will be employed to 35 
inform future directions of research. By combining this knowledge from oncology 36 
where the field of immunotherapy has now matured into clinical trials; it is hopeful 37 
that new mechanisms can be elucidated to generate targets for similar therapeutic 38 
strategies for women with hypertensive pregnancies where interventions are needed. 39 
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Introduction 41 
Hypertensive complications, including preeclampsia, pregnancy-induced 42 
hypertension (PIH) and maternal chronic hypertension, are the most common 43 
conditions encountered during pregnancy (1). Hypertension during pregnancy has a 44 
profound impact on the immediate and future health of both the mother and child.  In 45 
this review, the hypertensive complications of pregnancy are considered together 46 
and not as discrete entities. The presence of maternal chronic hypertension 47 
predisposes the development of preeclampsia and PIH (2); concurrently, the 48 
development of PE and PIH lead to an increased incidence of cardiovascular 49 
disease later in life (3). The development of hypertension during pregnancy confers 50 
increased risk of cardiovascular disease later in life (4); as do some forms of cancer 51 
(5); one mechanism that may link these conditions is the involvement of natural killer 52 
(NK) cells. While several aspects of the immune system could be involved, 53 
pathological changes in NK cells which are capable of recognizing and responding to 54 
ligands presented by the feto-placental unit during a normal pregnancy may facilitate 55 
communication between placental physiology and the maternal cardiovascular 56 
system. This review will focus on one particular member at the interface of the innate 57 
and adaptive immune system:  the natural killer (NK) cells. The aim of this review is 58 
to summarise the role of NK cells during healthy and hypertensive pregnancy and 59 
how the future direction of this field of research could benefit from what is known 60 
about these cells in oncology. 61 
Natural Killer Cell Biology 62 
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NK cells are lymphocytes that exhibit traits of both the innate and adaptive 63 
immune system that  differentiate and mature in the bone marrow, lymph nodes, 64 
spleen, tonsils, and thymus, where they then enter into the circulation (6). NK cells 65 
were once thought to be a unique example of an innate lymphoid cell (ILC); however 66 
recent work has identified that the NK cell belongs to a much larger family of ILCs 67 
and is representative of a heterogeneous immune cell population (7). NK cells have 68 
been divided into several groups depending on their cytokine profiles and functions 69 
which include cytotoxic and regulatory cells. Moreover, it is apparent that tissue 70 
resident NK cells may differ from classical peripheral blood NK cells. This distinction 71 
is particularly important at the maternal-fetal interface where uterine-specific uNK 72 
cells in the decidua have immunophenotypic and functional properties distinct from 73 
the peripheral blood NK cells (8). 74 
Cytotoxic NK cells, which form the majority (95%) of peripheral NK cells, are 75 
large granular lymphocytes defined in human peripheral blood as CD56Dim with 76 
potent cytotoxic ability (as their granules contain perforin and granzyme) and the 77 
ability to produce interferon γ (IFNγ) (9). In contrast, regulatory NK cells are 78 
agranular, smaller lymphocytes which are CD56Bright with limited cytotoxic ability but 79 
principally produce cytokines (such as IL-5, IL-13, TNFα, LT) upon activation (10). 80 
Other regulatory subsets of NK cells exist but are less well defined, they are 81 
principally characterised by the release of anti-inflammatory and regulatory cytokines 82 
such as transforming growth factor β1 (TGFβ1) and interleukin 10 (IL-10) (11). A 83 
similar attempt has been made to delineate cytotoxic and regulatory subtypes using 84 
CD27+/- as a marker in mice and Ly49s3 or NKR-P1B receptor in rats, however in 85 
both cases the distinction between the NK subsets is not as marked as in humans 86 
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(12). The remaining subsets of NK cells have not yet been subject to extensive pre-87 
clinical studies. This review will principally focus on the cytotoxic subset of NK cells.  88 
Spontaneous cytotoxic ability of NK cells is mediated through the 89 
perforin/granzyme B pathway leading to apoptosis and/or lysis of virus-infected or 90 
cancerous cells. They also produce a number of cytokines which recruit and regulate 91 
cells of the adaptive immune system (13). NK cells are described as immune 92 
sentinels and thus have a widespread distribution throughout the body. They are 93 
unique in that they are able to identify stressed or infected cells without antibody-94 
based recognition therefore providing a rapid immune reaction. NK cells normally 95 
represent a small percentage of the lymphocyte population, for example, 5-10% in 96 
the spleen and 2-18% of the peripheral blood mononuclear cell (PBMC) lymphocyte 97 
population in humans (14). The potent cytotoxic ability of NK cells is regulated on 98 
three levels. Firstly, NK cells undergo an education process whereby only those that 99 
recognise “self” are promoted to having cytotoxic ability (15). Secondly, these 100 
cytotoxic cells are tightly regulated by a sophisticated system involving a complex of 101 
interactions between the target cell and either activating or inhibitory receptors on 102 
the NK cell surface. NK cell surface receptors classically recognise MHC class I 103 
ligands as “self” or when these are up-regulated due to stress, “dangerous self”, or 104 
missing, “missing self”, such as during infection or in cancerous cells. Only NK cells 105 
that recognize “self” become tolerant, hence why they act when there is "dangerous 106 
self" or "missing self". NK cells can also recognise cell adhesion or virally-derived 107 
molecules. Finally, resting NK cells have a relatively low cytotoxic ability compared to 108 
“primed” NK cells. Priming involves a translational switch of the mRNA of cytotoxic 109 
molecules abundant in resting NK cells resulting in activation of the cytotoxicity (16). 110 
Priming is regulated by the cytokine microenvironment in which the NK cell is 111 
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present; such as type-1 interferons, IL-12, IL-18 and IL-15 to varying degrees in 112 
humans and rodents (17). It can also be regulated by close proximity of other 113 
immune cell types such as T cells, monocytes and dendritic cells (18-20).  114 
Receptors on NK cells belong to the family of killer cell Ig-like receptors (KIRs) 115 
and can be predicted to be either activating or inhibitory based upon a characteristic 116 
immune-receptor tyrosine-based activation or inhibitory motif; ITAM or ITIM, 117 
respectively. These specialised domains are phosphorylated by Src kinases resulting 118 
in the recruitment of scaffolding proteins for further signal transduction in the case of 119 
ITAMs; or recruitment of protein phosphatases to turn off signalling in ITIMs (21) . 120 
Whilst the general regulatory mechanisms of NK cell surface receptors are 121 
conserved between humans and rodents; the identity of these receptors are not 122 
directly comparable (Tables 1 & 2). For example, CD56, the main extracellular pan-123 
marker of NK cell populations in humans, is not expressed in rodents. In addition, 124 
receptors which are shared between species bind different ligands (12). Therefore, 125 
direct comparison of NK cell populations between rodents and humans requires 126 
care. Inter-species variation in cell surface receptors also exists between rats and 127 
mice. Additionally, further complexity exists as intra-species variation is observed in 128 
different strains of laboratory mice (22). 129 
Natural Killer Cells at the Maternal-Fetal Interface 130 
The study of NK cells in pregnancy has principally focused on the uterine 131 
specific population of these cells; known as uNK cells. These cells are considered to 132 
be a specialised, tissue-specific population whereby they exhibit a characteristic 133 
granular appearance but display significantly less cytotoxicity towards, for example, 134 
cancer cell lines  than peripheral NK cells (23), thus they do not normally kill the 135 
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invading trophoblast. This aspect of biology of uNK cells is particularly interesting as 136 
they still contain large granules with granzyme B and perforin, pointing to possible 137 
alternate functions in these unique NK cells. In contrast to peripheral blood NK cells, 138 
where CD16 allows for discrimination of cell cytotoxic and regulatory subsets, uNK 139 
cells in humans are almost exclusively CD16-CD56Bright (24); however, the uNK cell 140 
population does not fit exactly with the NK2 phenotype despite the CD56Bright 141 
phenotype but rather a variety of NK cell subtypes are represented. Both large 142 
granular and small agranular lymphocytes are identifiable microscopically, these 143 
uNK express a unique repertoire of receptors, and they have more potent cytokine 144 
producing ability (24). The major population of uNK cells in the decidua are of the 145 
TGFβ producing NK3 type; accounting for 20% of the uNK population (11). A similar 146 
characterisation of uNK cell markers has been conducted in mice which showed a 147 
unique CD3-CD122+NK1.1-DX5- population1 which was considered to represent 148 
murine uNK cells (25). In contrast to human uNK cells, murine uNK express high 149 
amounts of CD16 (25). A similar repertoire of receptors expressed by the rat uNK 150 
cell population has not yet been reported in the literature partly due to the limited 151 
commercial availability of rat-specific NK cell receptor antibodies, however ANK61 152 
(26) or perforin (27) has been used as a semi-quantitative measure for uNK cells 153 
using immunohistochemistry.  154 
The origins of uNK cells are of great interest, although remain unclear. They 155 
show ability to proliferate and differentiate from early NK progenitor cells or CD34+ 156 
cells which are recruited to uterine wall from blood (28). Residual endometrial NK 157 
cells may contribute (29) and/or mature NK cells may also be recruited during 158 
pregnancy upon release of paracrine factors from the trophoblast (30). These 159 
                                                          
1 NK1.1 is also known as CD161b/c and Ly55. DX5 is also known as CD49b. 
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diverse origins may also be reflected by morphological and functional diversity of the 160 
uNK cells. 161 
In humans, decidualisation occurs with each menstrual cycle but in rodents 162 
only occurs in response to implantation. Upon decidualisation, endometrial stromal 163 
cells become characteristically round in appearance and express factors such as 164 
prolactin, growth factors, pro-angiogenic factors and cytokines (IL-11 and IL-15) 165 
which stimulate the differentiation and proliferation of the uNK cell (31). 166 
Decidualisation is associated with a marked increase in NK cell number; 167 
approximately 75% of infiltrating leukocytes within the decidua are NK cells (24). The 168 
other 25% are composed of macrophages, few T cells and very few B cells (24). In 169 
addition to the invading trophoblast, uNK cells play an important role in maternal 170 
spiral artery remodelling. Compelling evidence of this is seen in pregnant mice which 171 
are genetically deficient for NK cells where the smooth muscle layer of the uterine 172 
spiral arteries remains intact (32). It has been shown in rats that the early increase in 173 
uNK cells directs early trophoblast invasion followed by a recession in number during 174 
mid-gestation where trophoblasts take over as the main effectors of vascular 175 
remodelling (33). However, recent work which employed antibody-based NK cell 176 
depletion in a rat model of preeclampsia did not replicate a deficiency in uterine 177 
spiral artery remodelling but did identify marked maternal uterine vasculopathy at a 178 
later time point in gestation (26). The uNK cells produce several key mediators of 179 
vascular remodelling ranging from IFNγ to matrix metalloproteinases (MMPs) and 180 
pro-angiogenic factors which can directly promote vascular remodelling (34). They 181 
also communicate with the invading trophoblast through the unique human leukocyte 182 
antigen (HLA) repertoire found on trophoblasts to indirectly mediate trophoblast-183 
dependent spiral artery remodelling (24). The interrogation of the underlying 184 
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mechanisms of uNK cell-mediated vascular remodelling is difficult due to the 185 
shallower trophoblast invasion seen in mouse models and the previously discussed 186 
strain-specific NK cell adaptations. Methodologically, there are no current knockout 187 
models which specifically deplete uNK cells or an antibody-based method of 188 
depleting this cell population in particular. 189 
Changes in peripheral NK cells do not directly mirror the status of uNK cells 190 
during pregnancy; therefore the two populations should be considered separately 191 
(11). Additionally, it has been shown that uNK cells, but not peripheral NK cells, can 192 
promote trophoblast invasion and decidual vascular remodelling (35). In humans, 193 
circulating NK cell numbers (total CD56+) are increased relative to non-pregnant 194 
women in the first trimester followed by a decline in late pregnancy. The cytotoxicity 195 
of these cells follows this pattern (36). A similar temporal study of peripheral NK cell 196 
number over pregnancy has not yet been reported in rodents. Alterations in 197 
peripheral NK cells have mostly been associated with recurrent pregnancy loss and 198 
infertility; however these findings are based on small, observational studies. A recent 199 
meta-analysis of the available literature indicated that an increase in peripheral NK 200 
cells, but not uNK cells, is seen in women with recurrent miscarriage. Notably, this 201 
analysis did not discriminate between CD56Bright and CD56Dim NK cells (37). The 202 
authors correctly identified that there is a pressing need for further research before 203 
immunotherapy should be used clinically (37). Other small studies have also 204 
explored a pro-inflammatory shift of NK cells in preeclampsia (38). In particular, IFNγ 205 
producing peripheral NK cells are increased in women with preeclampsia (39). 206 
Recent work has elucidated a causal role for IFNγ produced by NK cells in vascular 207 
dysfunction in an angiotensin II dependent mouse model of hypertension (40); such 208 
a mechanism has not been explored in hypertensive pregnancy. Whilst peripheral 209 
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NK cells may not play a major role in the vascular remodelling at the maternal-fetal 210 
interface, peripheral NK cells can produce vascular endothelial growth factor (VEGF) 211 
which is important for the maintenance and function of the systemic vasculature; this 212 
production has been shown to be impaired in women with preeclampsia (41). In pre-213 
clinical work, studies in a murine model that exhibit a 90% depletion of peripheral NK 214 
cells showed that maternal mean arterial pressure (MAP) was increased in mid-215 
gestation indicating that NK cells may play a role in blood pressure regulation (42). 216 
As the science which underpins our knowledge of peripheral NK cells and their role 217 
in pregnancy is, as yet, in its infancy looking to another field where NK cells are well 218 
assessed, such as oncology, may give us clues as to how to proceed in future 219 
research. 220 
NK-T Cells at the Maternal-Fetal Interface 221 
NK cell surface markers can also be expressed by a small group of T cells; 222 
these are defined as NK-T cells, and have completely distinct origin and effector 223 
functions although NK-T cell activity promotes NK cell activity by secreting IFNγ. The 224 
majority of NK-T cells are defined as invariant NK-T cells (iNKT) which uniquely 225 
express a semi-invariant T cell receptor (TCR) α chain which can be activated by the 226 
synthetic glycolipid α-galactosylceramide (43). A smaller, less-characterised 227 
population of non-invariant NK-T cells express diverse TCRs (non-iNKT) and have 228 
restricted expression and are not activated by α-galactosylceramide (43). NK-T cells 229 
are able to produce both Th1 and Th2 cytokines.  230 
NK-T cells have also been identified in the human and mouse decidua at a 231 
similar frequency of approximately 0.5% (43). Studies have shown that iNK-T cells 232 
may play a role in spontaneous pregnancy loss (44) but, thus far, this cell population 233 
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does not appear to be altered in the peripheral blood of women with hypertensive 234 
pregnancy (45). Non-iNK-T cells may play a regulatory role in trophoblast invasion 235 
and immune response in the decidua (46). 236 
Natural Killer Cells and Oncogenesis 237 
As sentinels of the immune system, NK cells are intrinsically involved in the 238 
identification and clearance of transformed cells. This role is thought to be principally 239 
fulfilled by the cytotoxic type population. Indeed, NK cells were first identified as a 240 
sub-population of lymphocytes derived from mice which exhibited spontaneous 241 
cytotoxicity against a cancer cell line (47). Pre-clinical experiments in NK cell 242 
deficient or depleted mice highlighted that these cells have an active role in 243 
immunosurveillance (9), directly limiting tumor growth and metastases (48) as well 244 
as identifying key cytokines (IL-2, IL-12, IL-15, IL-18 and IL-21) which promote the 245 
maturation and recruitment of NK cells leading to greater tumour clearance (49). In 246 
support of these findings, epidemiological studies in humans have also identified that 247 
both men and women with NK cells of naturally medium or high cytotoxicity have a 248 
reduced overall risk of developing any type of cancer relative to those individuals 249 
with low NK cell cytotoxic activity (50). The tumour microenvironment subverts the 250 
killing potential of these cells by releasing soluble factors such as TGFβ1 (51) as well 251 
as co-opting other immune cells such as T regulatory cells (Tregs) (52) or tumour-252 
associated fibroblasts to alter the behaviour of NK cells. With respect to their effector 253 
function, NK cells mediate the destruction of cancer cells in two ways: (i) directly 254 
through the granzyme B/perforin pathway or through activation of the TNF-related 255 
family of receptors (9); (ii) by expression of death receptor ligands such as FasL and 256 
TNF-related apoptosis-inducing ligand (TRAIL) and (iii) indirectly through recruitment 257 
and activation of other immune cells by production of chemokines and cytokines 258 
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such as  IFNγ and TNFα among others (53). These mechanisms are responsible for 259 
apoptosis and killing of virus infected cells or tumour cells. However tumour 260 
microenvironment can significantly affect NK cell function and allows for the failure of 261 
immune surveillance (54). Thus in similarity to placentation, NK cells are responsive 262 
to their environment which may create significant therapeutic opportunities in both 263 
conditions.  264 
Natural Killer Cells in Placentation and Cancer: Future Directions 265 
Research regarding the characterisation and role of peripheral NK cells in the 266 
hypertensive conditions of pregnancy lags behind the relatively well-developed 267 
cancer literature. Considering the fields of pregnancy and oncology together can be 268 
of mutual benefit; however, this review is centred upon pregnancy research.  A note 269 
of caution for interpreting both of these fields together is that the uNK cell population 270 
is a highly-specialised tissue specific group; drawing comparisons between 271 
peripheral NK cells only in cancer and pregnancy may be more appropriate. Further 272 
studies which span clinical samples and pre-clinical animal models are required to 273 
measure the presence of NK cells at the maternal-fetal interface and how this 274 
population affects the development and maintenance of the maternal-fetal interface 275 
and perhaps further afield in the maternal systemic vasculature.  The tumour 276 
microenvironment suppresses NK cell behaviour. Do such immunosuppressive 277 
mechanisms also exist in a physiological situation such as pregnancy where immune 278 
tolerance is vital and NK cells are intimately associated with the maternal-fetal 279 
interface? The TGFβ family are expressed in the trophoblast and early placenta (55) 280 
whilst a number of studies have proposed a link between mutations in the TGFβ 281 
gene and preeclampsia risk (56). TGFβ has also been shown to induce peripheral 282 
NK cells to show a uNK cell phenotype (57). The interaction between Tregs and NK 283 
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cells is subject to investigation whereby an increase in Tregs during pregnancy is 284 
considered to be beneficial to promote fetal tolerance (58).  285 
NK cells are professional cytotoxic lymphocytes and, in addition, can 286 
potentiate inflammation by the secretion of pro-inflammatory cytokines such as IFNγ 287 
and TNFα and through recruitment of other pro-inflammatory cells. This behaviour is 288 
common in a number of conditions such as cancer, cardiovascular (59) and 289 
autoimmune diseases (60). However, research into the actions of peripheral NK cells 290 
is lacking in the area of pregnancy and associated complications. Whilst 291 
immunotherapy is a well-developed area in cancer research reaching the stage of 292 
clinical trials; it is a relatively new area in treating pregnancy complications. Whilst 293 
cancer immunotherapy is focussed on the activation of peripheral NK cells to target 294 
and eliminate tumours, in contrast, immunotherapy during pregnancy should be 295 
focussed on suppressing the killer potential of these cells. Our own recent work has 296 
shown that treatment with etanercept, a TNFα antagonist, improves vascular function 297 
and pregnancy outcome in a rat model of chronic hypertension in pregnancy. One 298 
source of this detrimental TNFα was found to be peripheral NK cells present in both 299 
the circulation and placental tissue (61). In light of the current literature, it is clear 300 
that NK cells have a multifaceted role in pregnancy and a delicate balance exists 301 
between the regulatory and effector functions of this population of cells. Targets 302 
should be identified which are involved in the role of excess activation or number of 303 
detrimental NK cells that preserves the vital vascular remodelling and immune 304 
regulatory properties of uNK cells.  305 
In summary, NK cells are a diverse population with various regulatory and 306 
effector functions that are both context and tissue dependent. Nevertheless, there 307 
are properties of NK cells which are common in both the fields of placental biology 308 
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and oncology which may inform future research directions. Further, the newly 309 
described subsets of NK cells in humans have yet to be identified and characterised 310 
in rodents. New insight into these populations of NK cells and investigation into their 311 
role in the maintenance of health or pathology of various diseases is warranted. NK 312 
cells represent an emerging area of research which has the potential to elucidate 313 
new mechanisms and identify potential targets to treat hypertensive conditions of 314 
pregnancy where novel therapies are much needed. 315 
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Tables 508 
 509 
Table 1: Common Pan-Markers of NK Cells in Humans and Rodents 510 
 511 
Species Common Pan-Marker of NK Cell  
Human CD3- CD56+ 
Mouse CD3- CD49b+/CD122+ 
Rat CD3- CD161+/ANK61 
 512 
NK cell markers can also be expressed by a smaller subset of T cells therefore the absence of CD3 is 513 
a prerequisite for identifying NK cell populations. CD56, the main pan-marker for human NK cells, is not 514 
expressed in rodents. CD122 is a marker of NK cell lineage and is expressed at all stages of mouse 515 
NK development and CD49b (also known as DX5) is expressed on the majority of murine NK cells. 516 
CD161 (which binds NKR-P1A and NKR-P1B) are expressed on all rat NK cells. CD161 and ANK161 517 
antibodies are raised against the same antigen. 518 
 519 
 520 
Table 2: Major NK Cell Surface Receptor Families Differ between Humans and 521 
Rodents 522 
 523 
Humans Mice Rats 
NKR-P1A NKR-P1B/-D/-F/-G NKR-P1A/-B/-F/-G 
CD94/NKG2 CD94/NKG2 CD94/NKG2 
NKG2D NKG2D NKG2D 
KIR Ly49 Ly49 
Nkp46 Nkp46 Nkp46 
Nkp44 - - 
Nkp30 - Nkp30 
 524 
The NKR-P1 family were the first group of receptors to be characterised in NK cells. One inhibitory 525 
receptor, NKR-P1A, is present in humans whilst there is an extended family in mice (NKR-P1B/-D/-F/-526 
G) and in rats (NKR-P1A/-B/-F/-G) which act as either activating or inhibitory receptors. CD94/NKG2D 527 
expression in all species is dependent upon cytokine environment of the NK cells. NKG2D plays a major 528 
role in mediating cytotoxicity against transformed or stressed cells in all species. Human killer cell 529 
immunoglobulin-like receptors (KIRs) play a critical role in recognising the invading extravillous 530 
trophoblast; however these are not conserved in rodents. The rodent Ly49 receptors are functionally 531 
equivalent but structurally dissimilar to the human KIR family. The Nkp family are activating receptors 532 
which also play a key role in recognition and clearance of transformed cells. Nkp46 is expressed by all 533 
species whereas Nkp44 is human-specific and Nkp30 is in humans and rats only. 534 
 535 
